BIND Therapeutics & BIND RUS

Pharmaceuticals Based on the BIND Therapeutics’ Accurins™ Nanoplatform

Operating Factories

Shareholders in Portfolio Company 
RUSNANO, Flagship Ventures, Polaris Venture Partners, ARCH Venture Partners, NanoDimension, other investors

Industry Sector 
Medicine and Pharmacology

Production Location 
Khimki, Moscow Oblast
Jobs created: 20

Investment Started:  2011

Development and commercialization of a new class of highly selective targeted therapeutics based on BIND Therapeutics’s Accurins™ nanoplatform

BIND Therapeutics develops targeted therapeutics, called Accurins™, that selectively accumulate at the site of disease to dramatically enhance effectiveness for treating cancer and other diseases. BIND’s lead candidate, BIND-014, is in human clinical trials as a targeted therapy for cancer treatment. BIND’s development pipeline also includes other cancer treatments and drugs for anti-inflammatory and cardiovascular conditions.

Russia-based BIND RUS and its US parent, BIND Therapeutics, are responsible for developing BIND Accurins™ targeted delivery platform. The partial transfer of R&D to Russia and the involvement of local, highly qualified experts will boost the development of innovative drugs. These innovative pharmaceuticals will enter Russian and global markets simultaneously.

BIND’s patented Accurins™ platform together with Selecta Biosciences’s tSVP™ vaccine platform originated in laboratories at Harvard Medical School under the direction of Professor Omid Farokhzad, MD and in laboratories at MIT under the direction of Professor Robert S. Langer. Professor Langer’s lab is renowned for research work on targeted drug delivery technology. Robert Langer is a recipient of the National Medal of Science, the most prestigious honor for scientists bestowed by the United States, and an author of approximately 850 patents issued or pending worldwide.

Area of application

  • Treatment of oncological, cardio-vascular, inflammatory and other diseases

Market

  • Healthcare providers and their patients

Competitive advantages

  • Platform for rapid development of innovative pharmaceuticals
  • Highly effective drugs
  • Lower toxicity
  • Fewer side effects

Accurins™

BIND is discovering and developing AccurinsTM, proprietary new best-in-class therapeutics with superior target selectivity, and an improved therapeutic index.

Leveraging our proprietary Medicinal Nanoengineering® platform, we develop Accurins that outperform conventional systemic drugs by selectively accumulating in diseased tissues and cells. The result is higher drug concentrations at the site of action with minimal off-target exposure, leading to markedly better efficacy and safety.

Accurin Components

BIND's targeted Accurins consist of the following components that facilitate selective targeting of diseased cells and tissues:

  • Targeting ligand: The ability to attach targeting ligands to nanoparticles is a unique and valuable aspect of our technology. We develop targeting ligands that recognize specific disease-associated cell-surface proteins or receptors, enabling Accurins to preferentially accumulate at their intended site of action.
  • Stealth and protective layer: Engineered using proprietary methods for precisely controlling the Accurin surface characteristics, the stealth and protective layer shields targeted nanoparticles from immune surveillance, while providing attachment sites for the targeting ligand through proprietary linking chemistries.
  • Therapeutic payload (API): We can incorporate a broad range of active pharmaceutical ingredients into our targeted nanoparticles, including small molecules, peptides, proteins, and nucleic acids, such as siRNA.
  • Controlled-release polymers: The API payload is encapsulated in a matrix of clinically validated, biodegradable, and biocompatible polymers that mediate the release of the payload at the site of disease at an optimal rate.

Medicinal Nanoengineering® Platform

We create Accurins using a proprietary Medicinal Nanoengineering® platform that enables predictable, rapid design and optimization of targeted therapeutics with precisely controlled pharmacokinetic and biodistribution properties. We apply this platform to develop highly selective targeted therapeutics with unprecedented efficacy and tolerability.

The Medicinal Nanoengineering platform has demonstrated proof of concept across a broad range of drug classes and therapeutic areas. Preclinical studies validate the ability of our technology to improve the therapeutic index of cytotoxic agents, molecularly targeted anticancer drugs, and therapies for treating inflammation and pain.

The Medicinal Nanoengineering platform uses a combinatorial approach to design and engineer nanoparticles with optimal targeting and drug-release properties, and subsequent production of materials for drug development and commercialization:

  • We design combinatorial libraries of targeted nanoparticles with precise and systematically varied biophysicochemical properties such as particle size, surface properties, ligand density, drug load, and drug release profile, using a unique self-assembly nanoparticle fabrication process to optimize each product-for example, to balance circulation time with effective targeting and binding for a particular cell or tissue target.
  • We engineer product candidates with optimal performance properties using an iterative process that includes in vitro drug release and cell binding as along with in vivo PK, tolerability, biodistribution, targeting, and efficacy studies.
  • We manufacture candidate Accurins from gram-scale laboratory experiments through kilogram-scale GMP clinical batches using robust, reproducible, and scalable processes.

Accurin Targeting

Our technology incorporates a therapeutic payload into a nanoparticle and achieves targeting through a dual mechanism:

  1. Passive/Biophysical Targeting: We engineer biophysical properties of the nanoparticles to avoid immune surveillance and fit through gaps in blood vessels surrounding tumors and other disease sites
  2. Active/Ligand-Directed, Receptor-Mediated Binding: We attach a targeting ligand on the surface of the nanoparticle to bind to specific cell-surface markers.